AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.020

0.000

Volume:429.47K

Turnover:8.30K

Market Cap:70.88M

PE:-1.11

High:0.020

Open:0.020

Low:0.019

Close:0.020

52wk High:0.040

52wk Low:0.017

Shares:3.54B

Float Shares:2.86B

Volume Ratio:0.04

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-92.10%

ROA:-28.33%

PB:1.37

PE(LYR):-1.09

Loading ...

Overview Company News Filings

BRIEF-Radiopharm Theranostics Ltd May Offer & Sell Up To $50 Million From Time To Time In One Or More Offerings- SEC Filing

Radiopharm Theranostics Ltd May Offer & Sell up to $50 Mln From Time to Time in One or More Offerings- SEC Filing

THOMSON REUTERS

Radiopharm Theranostics Ltd: Achieves Primary Endpoint in 92% of Patients at Interim Analysis of Rad 101 Phase 2B Imaging Trial in Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics Reports 92% Success Rate for RAD 101 in Phase 2b Brain Metastases Trial

Radiopharm Theranostics Held General Meeting

Radiopharm Theranostics Appoints Bruce Goodwin as Director

Radiopharm Theranostics Ltd-Life Sciences Leader Bruce Goodwin Appointed to Board

THOMSON REUTERS

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of Rad 402 (Klk3-Mab With Tb161) in Advanced Prostate Cancer

THOMSON REUTERS

ASX Midday Sector Update: Information Technology Leads Selloff; Healthcare Bucks Downward Trend

MT Newswires Live

Radiopharm Theranostics Receives Ethics Committee Nod for Prostate Cancer Treatment Trial; Shares Down 4%

MT Newswires Live

Radiopharm Theranostics Ltd - Phase 2B Trial to Complete Enrollment and Have Topline Data in 1H26

THOMSON REUTERS

Radiopharm Theranostics Announces 50% Enrollment in Phase 2B Clinical Trial of Rad101 Imaging in Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics Says Phase 2 Brain Metastases Trial Reaches 50% Enrollment

MT Newswires Live

Radiopharm Theranostics Ltd-Rad Announces 50% Enrollment in Phase 2B Trial of Rad101

THOMSON REUTERS

Radiopharm Theranostics Starts Enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-Rad204

THOMSON REUTERS

Radiopharm Theranostics Completes Enrollment of Second Group of Patients in Cancer Trial; Shares Fall 4%

MT Newswires Live

Radiopharm Theranostics Unveils Pipeline Progress on First-in-Class Radiopharmaceuticals

Radiopharm Theranostics Ltd-Quarterly Activities/Appendix 4C Cash Flow Report

THOMSON REUTERS

Radiopharm Theranostics Updates on Clinical Trial Progress and Capital Raising

Radiopharm Theranostics Reports Positive Early Results Across Four Lead Clinical Programs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAD.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.02,"timestamp":1774588320000,"preClose":0.02,"halted":0,"volume":429473,"delay":0,"changeRate":0,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":2856071021,"shares":3544216000,"eps":-0.018,"marketStatus":"Market Closed","change":0,"latestTime":"03-27 16:12:00 AEDT","open":0.02,"high":0.02,"low":0.019,"amount":8303,"amplitude":0.05,"askPrice":0.02,"askSize":1117351,"bidPrice":0.019,"bidSize":1737453,"shortable":3,"etf":0,"ttmEps":-0.018,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.02,"openAndCloseTimeList":[[1774566000000,1774587600000]],"volumeRatio":0.04085628357759213,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.02,"auctionPrice":0.02,"auctionVolume":3048,"auction":3,"marketStatus":"盘后竞价","timestamp":1774588215608}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":2856071021,"roa":"-28.33%","roe":"-92.10%","lyrEps":-0.018424,"volumeRatio":0.04085628357759213,"shares":3544216000,"dividePrice":0,"high":0.02,"amplitude":0.05,"preClose":0.02,"low":0.019,"week52Low":0.017,"pbRate":"1.37","psRate":"4.35","week52High":0.04,"institutionHeld":0,"latestPrice":0.02,"committee":0.217214,"eps":-0.018,"divideRate":0,"volume":429473,"delay":0,"ttmEps":-0.018,"open":0.02,"prevYearClose":0.025,"prevWeekClose":0.02,"prevMonthClose":0.023,"prevQuarterClose":0.025,"fiveDayClose":0.02,"twentyDayClose":0.023,"sixtyDayClose":0.025,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592495847","title":"BRIEF-Radiopharm Theranostics Ltd May Offer & Sell Up To $50 Million From Time To Time In One Or More Offerings- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592495847","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592495847?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:22","pubTimestamp":1765923773,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Ltd May Offer & Sell Up To $50 Million From Time To Time In One Or More Offerings- SEC FilingDec 16  - Radiopharm Theranostics Ltd RAD.AX:RADIOPHARM THERANOSTICS LTD MAY OFFER & SELL UP TO $50 MILLION FROM TIME TO TIME IN ONE OR MORE OFFERINGS- SEC FILINGSource text: [ID:n0001213900-25-122349]Further company coverage: RAD.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM0XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"gpt_icon":1},{"id":"2592586479","title":"Radiopharm Theranostics Ltd May Offer & Sell up to $50 Mln From Time to Time in One or More Offerings- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592586479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592586479?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:13","pubTimestamp":1765923223,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM0XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2591180645","title":"Radiopharm Theranostics Ltd: Achieves Primary Endpoint in 92% of Patients at Interim Analysis of Rad 101 Phase 2B Imaging Trial in Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2591180645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591180645?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:06","pubTimestamp":1765800406,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2591645304","title":"Radiopharm Theranostics Reports 92% Success Rate for RAD 101 in Phase 2b Brain Metastases Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591645304","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591645304?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:00","pubTimestamp":1765800048,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd. announced interim results from its U.S. Phase 2b clinical imaging trial of RAD 101 in patients with brain metastases. According to the company, 92% of evaluable patients  achieved concordance with MRI imaging, meeting the primary endpoint of the study. RAD 101, a novel small-molecule imaging agent targeting fatty acid synthase  and radiolabelled with Fluorine-18, demonstrated significant and selective tumor uptake in suspected or recurrent brain metastases. The interim data have been presented by the company, and a webinar is scheduled to discuss the findings. Radiopharm Theranostics also indicated plans to initiate a pivotal study by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiophar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL3GjGv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","BK7067","BK4112","SG9999014039.USD","RAD.AU","SG9999014021.USD","SG9999014005.SGD","BK4588","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","LU0314104364.USD","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588488566","title":"Radiopharm Theranostics Held General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588488566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588488566?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:03","pubTimestamp":1764846209,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd. held a general meeting on December 3, 2025. Shareholders approved the ratification of the prior issue of First Tranche Placement Shares to placement participants. Approval was also granted for the issue of Second Tranche Placement Shares, the issue of Placement Attaching Options, and the issue of SPP Attaching Options. All proposals put forward at the meeting were carried.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL1WPyy8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2584949766","title":"Radiopharm Theranostics Appoints Bruce Goodwin as Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949766","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949766?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557238,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd. has announced the appointment of Bruce Goodwin as a new director, effective 19 November 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL9ggSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2584499367","title":"Radiopharm Theranostics Ltd-Life Sciences Leader Bruce Goodwin Appointed to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2584499367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584499367?lang=en_us&edition=fundamental","pubTime":"2025-11-19 09:43","pubTimestamp":1763516610,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUEBJNRS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2584939961","title":"Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of Rad 402 (Klk3-Mab With Tb161) in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584939961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584939961?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:08","pubTimestamp":1763464129,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2584047536","title":"ASX Midday Sector Update: Information Technology Leads Selloff; Healthcare Bucks Downward Trend","url":"https://stock-news.laohu8.com/highlight/detail?id=2584047536","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584047536?lang=en_us&edition=fundamental","pubTime":"2025-11-18 10:45","pubTimestamp":1763433918,"startTime":"0","endTime":"0","summary":"The healthcare sector was the only one in the green, gaining just 0.2% at midday Tuesday, after the S&P/ASX 200 index fell 131.30 points, or 1.5%, to 8,505.10, to the lowest point in five months.Minutes from the Reserve Bank of Australia's November meeting showed that the increase in inflation in the September quarter was larger than expected, and its monetary policy board affirmed that it was appropriate in this environment for its decisions to \"remain cautious and data dependent.\"Radiopharm Theranostics  received approval from the Bellberry Human Research Ethics Committee in Australia to start its first-in-human phase 1 clinical trial of RAD 402 for the potential treatment of prostate cancer.The information technology sector plummeted nearly 6%. The Nasdaq composite and S&P 500 indices fell nearly 1% on Wall Street, while the Dow Jones declined over 1%.Technology One , which fell over 16%, reported that its earnings per share in fiscal 2025 rose to AU$0.4173 from AU$0.3603 a year ear","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LU0029874061.USD","XAO.AU","XLV","BK4585","XJO.AU","LABU","BK4588","BK4581","XBI","BK7503","RAD.AU","HCSG","BK4137","III","TNE.AU","BK4134","BK7016","LU0128526141.USD","XKO.AU"],"gpt_icon":0},{"id":"2584018846","title":"Radiopharm Theranostics Receives Ethics Committee Nod for Prostate Cancer Treatment Trial; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584018846","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584018846?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:49","pubTimestamp":1763430582,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  received approval from the Bellberry Human Research Ethics Committee in Australia to start its first-in-human phase 1 clinical trial of RAD 402 for the potential treatment of prostate cancer, according to a Tuesday filing with the Australian bourse.Shares of the company fell past 4% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XKO.AU","BK7067","XJO.AU","RAD.AU"],"gpt_icon":0},{"id":"2584925625","title":"Radiopharm Theranostics Ltd - Phase 2B Trial to Complete Enrollment and Have Topline Data in 1H26","url":"https://stock-news.laohu8.com/highlight/detail?id=2584925625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584925625?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA6DZGB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2584625339","title":"Radiopharm Theranostics Announces 50% Enrollment in Phase 2B Clinical Trial of Rad101 Imaging in Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625339?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA6DZGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2584126615","title":"Radiopharm Theranostics Says Phase 2 Brain Metastases Trial Reaches 50% Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2584126615","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584126615?lang=en_us&edition=fundamental","pubTime":"2025-11-17 11:58","pubTimestamp":1763351929,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  said its phase 2b trial evaluating the diagnostic performance of RAD101 in patients with brain metastases achieved 50% enrollment, according to a Monday filing with the Australian bourse.The company expects to complete the enrollment and share top-line results in the first half of 2026, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","XKO.AU","XAO.AU","RAD.AU","XJO.AU"],"gpt_icon":0},{"id":"2584269652","title":"Radiopharm Theranostics Ltd-Rad Announces 50% Enrollment in Phase 2B Trial of Rad101","url":"https://stock-news.laohu8.com/highlight/detail?id=2584269652","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584269652?lang=en_us&edition=fundamental","pubTime":"2025-11-17 05:28","pubTimestamp":1763328520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nTUE1XCFWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2582371070","title":"Radiopharm Theranostics Starts Enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-Rad204","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371070?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:30","pubTimestamp":1762954201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA9R9BSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2582534537","title":"Radiopharm Theranostics Completes Enrollment of Second Group of Patients in Cancer Trial; Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582534537","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582534537?lang=en_us&edition=fundamental","pubTime":"2025-11-12 12:27","pubTimestamp":1762921628,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  said it completed the enrollment of the second group of patients in the first phase dose escalation trial of the lutetium-177-RAD204 therapy candidate in PD-L1 positive advanced cancers and started the enrollment of the third group, according to a Wednesday Australian bourse filing.Patients in the third group will receive a dose of 90 millicurie of lutetium-177, as approved by the data and safety monitoring committee, Chief Executive Riccardo Canevari said.The trial is targeting multiple tumor types, including non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, cutaneous melanoma, head and neck squamous cell carcinoma, and endometrial cancer, the filing said. It seeks to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and preliminary anti-tumour activities of lutetium-177-RAD204.Radiopharm Theranostics' shares fell over 4% in recent trading on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2582897943","title":"Radiopharm Theranostics Unveils Pipeline Progress on First-in-Class Radiopharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2582897943","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582897943?lang=en_us&edition=fundamental","pubTime":"2025-11-11 07:33","pubTimestamp":1762817602,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7qW9qq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2578607972","title":"Radiopharm Theranostics Ltd-Quarterly Activities/Appendix 4C Cash Flow Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2578607972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578607972?lang=en_us&edition=fundamental","pubTime":"2025-10-28 11:32","pubTimestamp":1761622346,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUE6KLVK3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2577899434","title":"Radiopharm Theranostics Updates on Clinical Trial Progress and Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2577899434","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577899434?lang=en_us&edition=fundamental","pubTime":"2025-10-21 05:59","pubTimestamp":1760997582,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd. has released a clinical update and details on capital raising. The presentation provides an overview of ongoing clinical trial progress, potential risks of trial delays, and considerations regarding regulatory requirements and associated costs. The company also outlines its recent capital raising activities. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL3L7Wth:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2576585959","title":"Radiopharm Theranostics Reports Positive Early Results Across Four Lead Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2576585959","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576585959?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:00","pubTimestamp":1760961634,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire  on October 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL2Q2652:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK7067","LU0314104364.USD","RAD.AU","LU2210149790.SGD","BK4112","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","NDAQ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}]}}